头颈鳞状细胞癌（HNSCC）是全世界最常见的恶性肿瘤之一，由于发生化疗耐药性，5年生存率改善较小。随着肿瘤免疫微环境引起的兴趣日益增加，免疫原性细胞死亡（ICD）诱导的化疗在增强免疫检查点抑制剂（ICI）的敏感性，改善肿瘤免疫治疗效果方面显示出有希望的结果。本综述总结了HNSCC化疗耐药性中重要ICD生物标志物的作用及其相关的分子机制。结果显示ICD启动可显着改善患者的生存和预后。ICD及其生物标记物也可作为肿瘤诊断和预后的分子标志物。此外，包括CALR、HGMB1和ATP在内的DAMPs的关键成分参与调节HNSCC化疗敏感性，证实ICD的关键生物标志物也可以成为调节HNSCC化疗耐药性的新靶点。本综述清晰地阐明了ICD生物标记物是参与HNSCC进展、化疗耐药性甚至免疫微环境调控的治疗靶点的假设的理论基础。编写和调查可能为HNSCC的分子治疗提供新的见解。版权所有©2023作者。由Elsevier Masson SAS发表，保留所有权利。

Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies in the whole world, with little improvement in the 5-year survival rate due to the occurrence of chemoresistance. With the increasing interests in tumor immune microenvironment, immunogenic cell death (ICD)-induced chemotherapy has shown promising results in enhancing sensitivity to immune checkpoint inhibitors (ICI) and improving the efficiency of tumor immunotherapy. This review summarizes the role of key ICD biomarkers and their underlying molecular mechanisms in HNSCC chemoresistance. The results showed that ICD initiation could significantly improve the survival and prognosis of patients. ICD and its biomarker could also serve as molecular markers for tumor diagnosis and prognosis. Moreover, key components of DAMPs including CALR, HGMB1, and ATP are involved in the regulation of HNSCC chemo-sensitivity, confirming that the key biomarkers of ICD can also be developed into new targets for regulating HNSCC chemoresistance. This review clearly illustrates the theoretical basis for the hypothesis that ICD biomarkers are therapeutic targets involved in HNSCC progression, chemoresistance, and even immune microenvironment regulation. The compilation and investigation may provide new insights into the molecular therapy of HNSCC.Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.